Women in Ophthalmology - 10 Minutes of Science

S01E09 Periocular Triamcinolone versus Intravitreal Triamcinolone versus Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular versus INTravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial

November 29, 2021 Women in Ophthalmology Season 1 Episode 9
Women in Ophthalmology - 10 Minutes of Science
S01E09 Periocular Triamcinolone versus Intravitreal Triamcinolone versus Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular versus INTravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial
Show Notes

Periocular Triamcinolone versus Intravitreal Triamcinolone versus Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular versus INTravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial

Dr Priya Samalia is a medical retina and uveitis fellow working at the Royal Victorian Eye and Ear Hospital. She examines the POINT trail on effectiveness of Periocular Triamcinolone vs. Intravitreal Triamcinolone vs. Intravitreal Dexamethasone Implant for the treatment of non-infectious uveitic macular oedema. Dr Samalia explains that the trail is important because macular oedema is a common cause of vision loss for patient with uveitis and management can be challenging. The paper is a head-to-head comparison and broadly represents a real-world patient mix. While it finds intravitreal treatments are superior, Dr Samalia notes there are valid reasons to perform periocular injections.

View article here